Baker Brothers Life Sciences LP
CIK 1363364 · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.39B
Companies
23
Total Filings
92
Lifetime Open-Market Net
$5.81B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MDGL | Director | 1,948,876 | $538.80 | $1.05B | $221.65M | 2 | 2026-06-18 |
| INCY | Director | 3,098,808 | $129.93 | $402.63M | $390.15M | 15 | 2026-01-05 |
| KYMR | Director | 7,955,916 | $106.16 | $844.60M | $1.03B | 1 | 2025-12-11 |
| PRLD | Director | — | $4.64 | — | $0 | 2 | 2025-06-13 |
| REPL | Director | — | $5.35 | — | $0 | 1 | 2025-03-07 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 3,759,462 | $1.27 | $4.77M | $0 | 5 | 2024-10-02 |
| VTVT | Director | — | $31.08 | — | $0 | 1 | 2024-06-27 |
| ACAD | Director | 39,452,627 | $26.01 | $1.03B | $900.00M | 4 | 2024-05-31 |
| BCYC | Director | — | $3.94 | — | $0 | 1 | 2024-05-29 |
| TCRX | Director | 104,698 | $0.77 | $81.0K | $128.25M | 3 | 2024-04-23 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 93,418 | $184.71 | $17.26M | -$1.19B | 3 | 2023-11-14 |
| Neurogene Inc. (NLTX) Delisted | Director | 116,457 | $13.96 | $1.63M | $160.87M | 2 | 2023-08-17 |
| KOD | Director | 1,143,396 | $40.29 | $46.07M | $1.08B | 4 | 2022-07-05 |
| DBVT | Director | 1,341,390 | $13.50 | $18.11M | $0 | 1 | 2022-06-13 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-06-10 |
| Talis Biomedical Corp (TLIS) Delisted | Director | 466,878 | $2.84 | $1.33M | $600.00M | 1 | 2021-02-19 |
| KNSA | Director | — | $79.44 | — | $0 | 1 | 2020-05-18 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 166,122 | — | — | -$403.77M | 11 | 2019-04-10 |
| Neurogene Inc. (AQXP) Delisted | Director | — | — | — | $0 | 1 | 2018-05-09 |
| Seagen Inc. (SGEN) Delisted | Director | 44,865,178 | $228.74 | $10.26B | $2.16B | 6 | 2018-05-02 |
| Aceragen, Inc. (IDRA) Delisted | Director | 242,126 | $7.22 | $1.75M | $0 | 8 | 2018-04-04 |
| XOMA | Director | 23,372 | $40.17 | $938.9K | -$62.10M | 5 | 2015-07-23 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 144,482 | — | — | $778.06M | 3 | 2015-01-09 |
Recent Filings · Page 2 of 10
92 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-08-20 | MDGL | Buy (P) | +582,390 | $221.65M | EDGAR |
| 2025-07-02 | INCY | Grant (A) | +5,904 | $0 | EDGAR |
| 2025-06-13 | PRLD | Grant (A) | — | $0 | EDGAR |
| 2025-03-07 | REPL | Grant (A) | — | $0 | EDGAR |
| 2025-02-28 | — | Notice (144) | −671,976 | -$174.71M | EDGAR |
| 2024-12-09 | — | Notice (144) | −950,907 | -$178.07M | EDGAR |
| 2024-10-02 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +23,928 | $0 | EDGAR |
| 2024-07-02 | INCY | Grant (A) | +6,444 | $0 | EDGAR |
| 2024-06-27 | VTVT | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | INCY | Mixed | −32,721,138 | -$1.97B | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.